Nuclear Medicine
177Lu PSMA (R+D)
Name:
177Lu PSMA (R+D)
Active Principle:
(2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid
Therapeutic Action:
Radiopharmaceutical used in the treatment of advanced metastatic castration-resistant prostate cancer that presents positive prostate-specific membrane antigen and has not responded effectively to treatment with other anticancer therapies.
Nuclear Medicine
177Lu PSMA (R+D)
Name:
177Lu PSMA (R+D)
Active Principle:
(2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid
Therapeutic Action:
Radiopharmaceutical used in the treatment of advanced metastatic castration-resistant prostate cancer that presents positive prostate-specific membrane antigen and has not responded effectively to treatment with other anticancer therapies.
